Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Ronopterin Misses Primary Endpoint In NOSTRA III Trial

03 Jun 2021

• By John Davis

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

The NOSTRA III study of Germany’s Vasopharm GmbH’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with traumatic brain injury (TBI), but the company believes the Phase III study has generated solid data that supports use of the compound within 12 hours of the injury, backed by a strong scientific rationale.

Vasopharm announced the top-line results from NOSTRA III on 3 June and said it intends to discuss the findings with...